Use of aerosolized compounds in the treatment of exercise induced pulmonary hemorrhage in an equine
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Apr 17, 2003
app pub date -
Oct 14, 2002
filing date -
Oct 12, 2001
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The administration of aerosolized nitric oxide donors or type V phosphodiesterase inhibitor in controlled doses to horses during high intensity exercise is described. Aerosolized nitric oxide donors (in conjunction with intravenous type V phosphodiesterase inhibitor) and type V phosphodiesterase inhibitor are beneficial to prevent exercise induced pulmonary hemorrhage by reducing transmural pulmonary artery pressure with a concomitant decrease in pulmonary capillary stress failure. The administration of aerosolized nitric oxide donors and type V phosphodiesterase inhibitors is viewed as a novel therapeutic modality in the alleviation of capillary stress failure and EIPH in performance horses.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully